<DOC>
	<DOCNO>NCT02808026</DOCNO>
	<brief_summary>To examine antihypertensive effect safety administration CS-3150 patient severe hypertension ( Grade III ) .</brief_summary>
	<brief_title>Study CS-3150 Patients With Severe Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Male female subject age 20 80 year informed consent Subjects severe hypertension , receive antihypertensive drug receive antihypertensive drug ( except potassiumsparing diuretic ) runin period ( Sitting SBP ≥ 180 mmHg Sitting DBP ≥ 110 mmHg ) Patients suspect hypertensive emergency Secondary hypertension malignant hypertension Diabetes mellitus albuminuria Serum potassium level &lt; 3.5 ≥ 5.1 mEq/L ( ≥ 4.8 mEq/L receive RA inhibitor ) eGFR &lt; 60 mL/min/1.73 m^2 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>severe hypertension</keyword>
	<keyword>grade III hypertension</keyword>
	<keyword>mineralocorticoid receptor antagonist</keyword>
</DOC>